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Abstract
Background: Interferon lambdas (IFNLs) have important anti-viral/bacterial and immunomodulatory functions in
the respiratory tract. How do IFNLs impact COPD and its exacerbations?
Methods: Five hundred twenty eight patients were recruited in a prospective observational multicentre cohort
(PROMISE) study. The genetic polymorphisms (rs8099917 and rs12979860) within the IFNL3/4 gene region and
circulating levels of IFNL3 in COPD patients were determined and associated with disease activity and outcome
during a median follow-up of 24 months.
Results: The GG genotype significantly influenced severe exacerbation rate (42 vs. 23%; p = 0.032) and time to
severe exacerbation (HR = 2.260; p = 0.012). Compared to the TT or TG genotypes, the GG genotype was associated
with severe dyspnoea (modified medical research council score ≥ median 3; 22 vs 42%, p = 0.030). The CC
genotype of the rs12979860 SNP was associated with a poorer prognosis (body mass index, airflow obstruction,
dyspnea and exercise capacity index ≥ median 4; 46 vs. 36% TC vs. 20.5% TT; p = 0.031). Patients with stable COPD
and at exacerbation had significantly lower circulating IFNL3 compared to healthy controls (p < 0.001 and p < 0.
001, respectively). Circulating IFNL3 correlated to post-bronchodilator FEV1%predicted and the tissue maturation
biomarker Pro-collagen 3.
Conclusion: IFNL3/4 polymorphisms and circulating IFNL3 may be associated with disease activity and outcomes in
COPD.
Trial registration: Clinical Trial registration http://www.isrctn.com/ identifier ISRCTN99586989 on 16 April 2008.
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Background
Interferons (IFN) are known to have important direct
anti-viral and anti-bacterial effects, as well as potent
modulatory effects on the adaptive immune response via
the induction of hundreds of IFN-stimulated genes
(ISGs) [1, 2] The newest discovered class of IFN, the
IFN lambda (IFNL) family, has four members: IFNL1–4
[3]. The IFNL receptor consists of a heterodimer with an
alpha subunit (IL28RA) and a beta subunit (IL10RB).
IL10RB is ubiquitously expressed, whereas IL28RA ex-
pression is restricted and interestingly, it is highly
expressed on lung epithelial cells [4] and alveolar macro-
phages [5]. When a virus is seen by the pattern recogni-
tion receptors which are found on macrophages and
epithelial cells, IFNL gene expression is stimulated via
various signalling pathways [6]. This leads to increased
circulating IFNL3 which interacts with the IFNL recep-
tor expressed on lung, intestinal and liver cells, and via
the JAK-STAT signalling cascade induces interferon
stimulated genes which in turn influence viral
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replication [6]. A series of single nucleotide polymor-
phisms (SNPs) in the IFNL3/4 gene region have been
described [7–9] and associated with variable IFNL3/4
gene expression [10–13]. The variability of IFNL3 during
viral or bacterial infections may lead to significant differ-
ences in the subsequent immune response and thus vari-
able clinical outcomes [3].
IFNL3 has immune-modulatory and anti-tumorigenic
effects and is induced by viral infections [6, 14]. Viral in-
fections play an important role in the exacerbation of
asthma [15–17] and COPD [18–20]. Reduced interferon
activity during a respiratory syncytial virus infection has
been linked to the later development of asthma in chil-
dren [20, 21]. The mechanism of virus-induced exacer-
bations of COPD is not well-defined. Recently, the role
of IFNLs in the exacerbation of asthma has been ex-
plored [22–24]. However, no data are available regarding
the effect of IFNL3 or its polymorphisms on the exacer-
bation and further clinical outcomes of COPD. COPD
patients exposed to rhinovirus consistently showed a
trend towards less IFNL expression in bronchoalveolar
lavage fluid [25] and in animal models it has been shown
that IFNL plays a role in viral (influenza A, coronavirus
and rotavirus) modulation [6].
We hypothesize, that in patients with COPD, SNPs in
the IFNL3/4 gene will impact clinical outcomes such as
exacerbation and that they might be associated with cir-
culating markers of inflammation and tissue remodel-
ling. Therefore, we aimed to explore the IFNL3/4
polymorphisms (rs8099917 and rs12979860) and circu-
lating IFNL3 in association with the occurrence of ex-
acerbation of COPD and all-cause mortality in a
multinational, multicenter, prospective, longitudinal, ob-
servational cohort study of patients with clinically stable
and exacerbated COPD.
Methods
Study overview
Patients in stable state COPD with GOLD II to IV were
enrolled for an observational prospective trial (PROMISE-
COPD; www.controlled-trials.com identifier ISRCTN9
9586989). The study details have been published previ-
ously [26]. For the current nested biomarker study, 638
patients were consecutively recruited and followed at 11
European hospital pneumology departments from No-
vember 2008 to October 2011 (Fig. 1). Details of inclusion
and exclusion criteria were previously published [27]. We
analysed data from 528 patients, who completed the first
6 month-follow-up of the study and for whom serum
samples from visit 1 were available. We used serum sam-
ples at the stable phase and during the first episode of ex-
acerbation of COPD.
For each patient, a physical examination was per-
formed, vital signs were registered, and a detailed history
Fig. 1 Flow chart of the patient cohort selection criteria
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obtained. Spirometry and 6-min walk tests (6MWTs)
were performed following American Thoracic Society
guidelines [24, 25]. One- and two-year follow-up in a
stable phase, including a series of outcome markers were
determined as previously published [26]. Additionally,
patients treated for infection-triggered exacerbation of
COPD had a scheduled follow-up four weeks post-
exacerbation onset. Acute exacerbations were defined as
an acute sustained worsening of dyspnoea, cough and/or
sputum beyond normal day-to-day variations in a patient
with underlying COPD; severe exacerbations were de-
fined as an exacerbation requiring hospitalisation [28]. A
total of 30 age and gender unmatched healthy controls
were included in the study.
Ethics
The study was an observational study without specific
intervention. The IFNL3 genotypes and serum levels
were retrospectively determined and had no impact on
the treatment decisions. The study was approved by the
respective participating local IRBs in all centers (Ethik-
kommission beider Basel EKBB/295707, Medical Ethical
Committee Amphia Ziekenhuis 958, Medical Ethical
Committee North Holland M08–016, Klinicki Centar
Srbije Eticki Odbor, Clinical Research Ethics Committee
Germans Trias I Pujol Hospital, Medizinische Hochschule
Hannover Ethikkommission 5071, Ethics committee of
the Hospital Clinic of Barcelona, Ethics committee of the
Policlinico of Milan, Ethics committee in Greece). All pa-
tients provided a written informed consent.
IFNL3 ELISA assay
IFNL3 serum levels were determined in the stable phase
and during exacerbation of COPD. A commercially
available sandwich immunoassay ELISA kit that showed
no cross-reactivity with IFNL2 (IL28A) or IFNL4 (IL29;
Human IL-28B/IFN-lambda 3 DuoSet ELISA, DY5259,
R&D Systems Minneapolis, MN, USA) was used, accord-
ing to the manufacturer’s instructions. The IFNL3 assay
had a linear range of detection from 31.20–2000 pg/ml.
IFNL genotyping
Two common SNPs, rs8099917 and rs12979860, in the
IFNL3/L4 gene regions were determined as previously
described [11]. The distribution of minor and major al-
lele genotypes is comparable to previous publications in
European populations [29, 30].
Collagen markers
As previously described [31], serum levels of fragments
of collagen type III (C3M), fragments of collagen type VI
(C6M), pro-form of collagen type III (Pro-C3) and pro-
form of collagen type VI (Pro-C6) were measured with
Nordic Bioscience assays according to the manufac-
turer’s instructions.
Inflammatory markers
Procalcitonin, Copeptin, pro-adrenomedullin (ADM),
and atrial natriuretic polypeptide (ANP) were measured
as previously described [32].
Statistics
Differences in dichotomous variables were evaluated
using the Chi-square test or Fischer’s exact test, as ap-
propriate. Normally distributed parameters were ana-
lyzed using the Student’s t-test for equality of means. All
other continuously non-normally distributed parameters
were evaluated using the non-parametric Mann-Whitney
U test or Kruskal-Wallis test, as appropriate. If the
IFNL3 was below the detection level, the sample was
assigned the value 31.20 pg/ml which is the lowest de-
tectable value with the assay used in this study. Kaplan
Meier curves were created to determine survival within
2 years and overall survival, occurrence of exacerbation
and occurrence of severe exacerbation. The log-rank test
was used to compare differences between survival
curves. The Statistical Package for Social Sciences Pro-
gram (SSPS Inc., version 22 for Windows) was used. All
tests are two-tailed; a p-value of < 0.05 was considered
significant. Results are expressed as mean (standard de-
viation) or median (interquartile range), unless otherwise
stated.
Results
Five hundred twenty eight patients were included in this
nested study (Fig. 1). The majority of the patients were
male (71%) and the average age was 66.9 years (Table 1).
70% of the patients were past smokers and 50% of the
patients were classified as GOLD II.
IFNL3 genotyping
The distribution of both rs8099917 and rs12979860
SNPs adhered to the Hardy Weinberg Equilibrium with
the χ2 test for deviation equalling 2.21 for rs8099917
and 0.781 for rs12979860. Both values were less than
3.84 which represents the 5% significance level for 1 de-
gree of freedom and therefore the null hypothesis that
the population is in the Hardy-Weinberg frequencies is
not rejected [33]. The most common genotype
rs8099917 TT (65%) was followed by TG (30%) and GG
(5%; Table 1).
Patients with the rs8099917 GG genotype had a sig-
nificantly shorter time to severe exacerbation than pa-
tients with the TT or TG genotype (Fig. 2; p = 0.037).
Significantly more severe exacerbations occurred in pa-
tients with rs8099917 GG genotype compared to pa-
tients with rs8099917 TT or rs8099917 TG genotype (42
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vs 23%, respectively; chi-squared p = 0.032). The
rs8099917 genotypes had no significant effect on mortal-
ity (p = 0.726). There was a significant association be-
tween MMRC and the rs8099917 GG genotype with
42% (11/26) of patients with the GG genotype having an
MMRC more than the median compared to 22% (107/
479) of patients with rs8099917 TT or rs8099917 TG
Table 1 Baseline characteristics of patients included in the study
Mean (SD), n (%)
Gender: Male 377 (71)
Age, years 66.9 (9.3)
Current smoker, n (%) 157 (30)
BMI (kg/m2) 26.00 (5.13)
Unadjusted Charlson Score (n = 528) 1.82 (1–16)
BODE index (median; IQR) 3 (1–4)
6MWT (m) 380.61 (104.69)
Exacerbation rate 2.05 (0–15)
Severe exacerbation rate 0.39 (0–8)
Lung function (post-brd)
FEV1, in L 1.40 (0.71)
FVC, in L 2.81 (0.89)
FEV1/FVC% 47.87 (13.97)
FEV1, % predicted 49.89 (16.8)
FVC, % predicted 80.70 (21.21)
Collagen markers [ng/ml]
C3M 30.54 (12.61)
C6M 15.25 (8.62)
Pro-C3 13.29 (10.03)
Pro-C6 8.76 (4.31)
EL-NE 7.78 (6.78)
GOLD Gradea
GOLD II 262 (50)
GOLD III 180 (35)
GOLD IV 80 (15)
rs8099917 genotypes
TT 339 (65)
GG 26 (5)
TG 155 (30)
rs12979860 genotypes
CC 76 (30)
TT 45 (18)
TC 131 (52)
MMRC score (median; IQR) 2 (1–2)
Inflammation markers at baseline
Copeptin, pMol/L 12.57 (16.66)
Adrenomedullin, nMol/L 0.69 (0.38)
Atrial Natriuretic Peptide, pMol/L 113.67 (101.03)
Procalcitonin, μg/l 0.09 (0.14)
SF-36
Physical function 51.54 (25.94)
Role physical 51.05 (43.48)
Role emotional 66.26 (43.52)
Social Functioning 69.49 (28.56)
Table 1 Baseline characteristics of patients included in the study
(Continued)
Mean (SD), n (%)
Mental Health 64.89 (20.07)
Body Pain 74.19 (27.94)
Vitality 51.79 (21.00)
General Health 47.88 (22.90)
SGRQ
Symptoms score 49.30 (22.65)
Activity score 57.22 (22.90)
Impacts score 32.11 (18.66)
Total score 42.39 (18.11)
Continuous data are shown as mean (SD) or median (interquartile range) and
categorical variables as No. (%). BMI = body mass index; brd = bronchodilator;
BODE = BMI, airflow obstruction, dyspnea and exercise capacity; 6MWD = 6-
min walk distance; C3M = fragments of collagen type III; C6M = fragments of
collagen type VI; Pro-C3 = pro-forms of collagen type III; Pro-C6 = pro-forms of
collagen type VI; EL-NE = neutrophil elastase-generated fragments of elastin;
GOLD = Gold Initiative for Chronic Obstructive Lung Disease; MMRC =
modified Medical Research Council; SF-36 = 36-item Short-Form Health Survey;
SGRQ = St. George’s Respiratory Questionnaire
aGOLD grades are based on FEV1% predicted: 50% ≤ II ≤ 80%; 30% ≤ III ≤
50%; and IV ≤ 30%
Fig. 2 Kaplan Meier curve showing the significant effect of the
rs8099917 GG genotype on time to severe exacerbation; p = 0.037. GG
p = 26, 11 events; TT n = 335, events = 73; TG n = 154, events = 39
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genotype (Table 2; chi-squared, p = 0.030). Although
there was no difference in the unadjusted Charlson score
(p = 0.705), suggesting a similar distribution of comor-
bidities and life expectancy between the groups, five
times the number of patients with rs8099917 GG geno-
type had been diagnosed with a malignancy at the start
of the study compared to patients with rs8099917 TT or
rs8099917 TG genotype (chi-squared, p = 0.014). The
association between rs8099917 GG genotype and having
a malignancy remained after adjusting for age and smok-
ing (OR = 6.726, p = 0.003). Mann-Whitney-U-Test
showed a significant difference in C6M between
rs8099917 GG genotype and rs8099917 TT/TG geno-
type (Table 2).
The rs12979860 genotypes had no effect on mortality
(p = 0.703), exacerbation rate (p = 0.946) or time to ex-
acerbation (p = 0.324). The rs12979860 CC genotype
was associated with BODE index with 46% (30/65) of
the patients with a BODE index more than the median
compared to 36% (44/122) of patients with the
rs12979860 TC and 20.5% (8/39) of patients with the
rs12979860 TT genotype (p = 0.031).
Circulating IFNL3 in serum
Circulating IFNL3 was detectable in 3.6% (19/528) of the
COPD patients during stable phase and in 7.2% (32/446)
of the COPD patients during the exacerbation phase
whereas it was detectable in 80% (24/30) of the blood
samples from healthy controls. The level of IFNL3 was
higher in the controls compared to the COPD patients
during stable phase, exacerbation phase and follow-up to
the exacerbation (Fig. 3).
There was no association between the rs8099917 (chi-
square test; p = 0.392) or rs12979860 genotypes (chi-
square test; p = 0.733) and whether IFNL3 was detect-
able or not during the stable phase.
Circulating IFNL3 during stable COPD phase
None of the patients with a GOLD IV classification had
detectable circulating IFNL3 during stable phase. 3% (5/
180) of the patients classified as GOLD III and 5% (14/
262) of the patients classified as GOLD II had detectable
circulating IFNL3 levels. GOLD II (31.2 pg/ml; Range =
undetectable – 661.83) and GOLD III (31.2 pg/ml;
Range = undetectable – 122.26) patients had similar
levels of circulating IFNL3, which was less than in
healthy controls (82.7 pg/ml; IQR = 81.9–83.4). Using a
Mann-Whitney-U-test, patients with detectable circulat-
ing IFNL3 had significantly better post-bronchodilator
FEV1%predicted than patients with undetectable IFNL3
(57.97 vs. 49.62; p = 0.035). We found a significant cor-
relation between circulating IFNL3 and post broncho-
dilator FEV1%predicted (Spearman Rho = 0.098; p =
0.034). There was no significant difference in other
variables, including quality of life, between patients with
detectable circulating IFNL3 and patients with non-
detectable circulating IFNL3.
Circulating IFNL3 and collagen biomarkers
There was a significant association between circulating
IFNL3 and Pro-C3 (Linear regression, Beta = 0.099 95%
CI 0.037–0.634; p = 0.028) but no association with C3M,
C6Mor Pro-C6. Patients with detectable circulating
IFNL3 had significantly more Pro-C3 than patients with
undetectable levels of IFNL3 (Mann-Whitney U-Test,
median 16.1 [IQR = 8.0] vs 10.7 [IQR = 5.6] ng/ml, re-
spectively; p = 0.003). There was no significant differ-
ence in the other collagen biomarkers between the two
groups of patients.
Discussion
Viral infections are thought to play a role in the exacer-
bation of COPD [18, 19]. IFNL3, a member of the inter-
feron lambda family, has immune-modulatory and anti-
tumorigenic effects and is induced by viral infections
[14]. This is the first study evaluating the association be-
tween IFNL circulating levels and its polymorphisms in
patients with COPD.
The distribution of both rs8099917 and rs12979860
SNPs adhered to the Hardy Weinberg Equilibrium. Eth-
nic background strongly impacts SNP distribution, how-
ever, people with Caucasian ancestry (the main ethnic
background of the present cohort) have a more balanced
distribution of genetic polymorphisms [9, 34]. In our
COPD cohort, the SNP rs8099917 GG genotype signifi-
cantly influenced the severe exacerbation rate, and the
time to severe exacerbation and it was associated with a
higher MMRC score. Conversely, SNP rs12979860 had
no effect on exacerbations or death. This is in line with
what is known for hepatitis and diabetes, where the SNP
rs8099917 GG genotype is considered to be the risk
genotype and the SNP rs12979860 CC genotype the pro-
tective genotype [35–37]. The IFNL3 polymorphisms
predict response to treatment in patients with hepatitis
C [27, 30, 31]. We found that the prevalence of malig-
nancy was increased among patients with the rs8099917
GG genotype. This was also seen in patients with
chronic hepatitis C, where more patients with the
rs8099917 GG or non-TT genotype had hepatocellular
carcinoma [38]. In antiretroviral-treated HIV-infected
patients, however, the SNP rs12979860 CC genotype was
associated with higher mortality and thus it was not pro-
tective [39]. In COPD patients, we found that the SNP
rs12979860 CC genotype was associated with a higher
BODE index, and thus possibly a higher risk of mortal-
ity, though the rs12979860 CC genotype did not associ-
ate with mortality directly in this study.
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Table 2 A comparison of the patient baseline characteristics according to their rs8099917 genotype
GG (median, IQR) TT/TG (median, IQR) p-value
Gender: Male (n,%) 16 (61.5) 355 (71.9) 0.269
Age, years 70.50 (14.50) 67.00 (13) 0.139
Current smoker (n, %) 4 (15.4) 149 (30.3) 0.125
PY, months 40.00 (36.75) 45.00 (35) 0.261
BMI, kg/m2 27.29 (7.83) 25.86 (6.14) 0.339
Unadjusted Charlson Score 1.00 (2.00) 1.00 (1.00) 0.305
6MWT, m 375 (161.25) 395 (120) 0.362
Exacerbation rate (number of exacerbations/year) 2.00 (3.00) 1.00 (3.00) 0.935
Severe exacerbation rate (number of severe exacerbations/year) 0.58 (0–3) 0.37 (0–8) 0.033
Lung function (post-brd)
FEV1, in L 1.31 (0.8) 1.32 (0.74) 0.749
FVC, in L 2.53 (1.95) 2.69 (1.07) 0.688
FEV1/FVC% 49.38 (27.47) 47.00 (22.91) 0.723
FEV1, % predicted 56.50 (28.17) 49.50 (25.15) 0.314
FVC, % predicted 82.40 (42.75) 80.00 (26.22) 0.349
BODE index 0.659
≤ median of 3 15 (62.5) 302 (67.3)
> median of 3 9 (37.5) 147 (32.7)
Collagen markers [ng/ml]
C3M 25.3 (14.5) 28.6 (11.6) 0.302
C6M 11.0 (9.7) 13.3 (8.1) 0.032
Pro-C3 12.1 (6.1) 10.8 (5.6) 0.684
Pro-C6 8.1 (3.7) 8.0 (0.535) 1.000
GOLD Gradea (n,%) 0.699
GOLD II 15 (57.7) 242 (49.6)
GOLD III 8 (30.8) 169 (34.6)
GOLD IV 3 (11.5) 77 (15.8)
MMRC Test (n,%) 0.030
≤ median of 2 15 (57.7) 372 (77.7)
> median of 2 11 (42.3) 107 (22.3)
Inflammation markers
Copeptin, pMol/l 8.24 (10.45) 8.57 (12.53) 0.465
Adrenomedullin, nMol/l 0.60 (0.28) 0.60 (0.3) 0.929
ANP, pMol/l 91.38 (52.43) 83.47 (83.18) 0.408
Procalcitonin, μg/l 0.08 (0.03) 0.08 (0.03) 0.862
SF-36
Physical function 45 (47.5) 50 (45) 0.346
Role physical 50 (100) 50 (100) 0.742
Role emotional 100 (75) 100 (100) 0.518
Social Functioning 75 (65.6) 75 (50) 0.852
Mental Health 67.50 (36.25) 65 (27.50) 0.780
Body Pain 80 (58) 80 (48) 0.720
Vitality 46.88 (32.81) 50 (31.25) 0.403
General Health 37.50 (42.5) 50 (36.69) 0.570
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We found no association between the genotype and
the circulating IFNL3 levels. In the literature, the associ-
ation between genotype and circulating IFNL3 levels var-
ies according to illness and group. Arpaci et al. [40]
found no association between genotype and circulating
IFNL3 in patients with Hashimoto’s Thyroiditis. Lan-
ghans et al. [41] found that hepatitis C patients with the
protective SNP rs12979860 CC genotype had more cir-
culating IFNL3 compared to patients with the SNP
rs12979860 TT genotype whereas Alborzi A., et al. [42]
found no association between circulating IFNL3 and
genotype.
Less IFNL3 is secreted by primary cells from asthmatic
patients compared to cells from healthy controls infected
with a virus but the basal levels are similar between the
two groups [22]. Bullens et al. [43] found increased basal
IFNL3 mRNA in the sputum of asthmatic patients com-
pared to controls. Thus far there is no literature regard-
ing basal serum IFNL3 levels in asthma patients
compared to controls. Circulating IFNL3 levels were
similar between hepatitis C patients and healthy controls
[41] and Arpaci et al. [40] found increased basal circulat-
ing IFNL3 in patients with Hashimoto’s thyroiditis
compared to healthy controls. In our cohort of COPD
patients, basal circulating IFNL3 levels were significantly
less compared to controls. The circulating IFNL3 levels
increased during an exacerbation, as was also seen in
vitro in the cells from asthmatic patients that were in-
fected with virus [22], and then returned to basal levels
after the patient had recovered from the exacerbation. In
COPD, the basal circulating IFNL3 levels were associ-
ated with the severity of airflow limitation. We hypothe-
sise that the difference in circulating IFNL3 between
healthy donors, GOLD II, GOLD III and GOLD IV pa-
tients may be due not only to the association between
IFNL3 and FEV1, but also due to remodelling of the
extracellular matrix in the lungs. This hypothesis is in
part corroborated by the fact that there is a strong asso-
ciation between circulating IFNL3 and Pro-C3. Pro-C3 is
the N-protease cleavage site of type III collagen and is a
marker of tissue formation [44]. Low levels of Pro-C3 is
associated with worse lung function [31, 45] and with a
shorter time to severe exacerbation [31]. It is therefore
possible that changes in the cell structure of the lung re-
sults in decreased secreted IFNL3 which causes an
impaired immune response to infection. More exacerba-
tions occur resulting in more remodelling of the cells
and less IFNL3 secretion, both of which are associated
with impaired lung function, and a vicious cycle is con-
tinued. It is also possible that the decreased circulating
IFNL3 facilitates viral infection leading to less Pro-C3
which results in worse lung function and shorter time to
exacerbation. We are unable to determine which elem-
ent is the catalyst therefore further studies are required
to explore the association between IFNL3 polymor-
phisms and the remodelling of the extra-cellular matrix
in stable and exacerbated COPD.
We found no association between circulating IFNL3
levels and disease outcome as is also evident in patients
with hepatitis C [41].
The main limitation to this study is that there are no
genotyping results for healthy controls and the SNP data
was not validated in a separate cohort. We only investi-
gated two SNPs, further studies are needed to investigate
Table 2 A comparison of the patient baseline characteristics according to their rs8099917 genotype (Continued)
GG (median, IQR) TT/TG (median, IQR) p-value
SGRQ
Symptoms score 46.60 (26.87) 49.72 (34.44) 0.356
Activity score 66.19 (31.99) 54.43 (31.81) 0.607
Impact score 29.16 (25.68) 29.39 (26.46) 0.802
Total score 44.15 (31.27) 39.03 (27.54) 0.892
Continuous data are shown as median (interquartile range) and categorical variables as No. (%). Italicized p-values are statistically significant, ie. p < 0.05. BMI body
mass index, brd bronchodilator, BODE BMI, airflow obstruction, dyspnea and exercise capacity; 6MWD 6-min walk distance, C3M fragments of collagen type III, C6M
fragments of collagen type VI, Pro-C3 pro-forms of collagen type III, Pro-C6 pro-forms of collagen type VI, GOLD Gold Initiative for Chronic Obstructive Lung Disease,
MMRC modified Medical Research Council, ANP Atrial Natriuretic Peptide, SF-36 36-item Short-Form Health Survey, SGRQ St. George’s Respiratory Questionnaire
aGOLD grades are based on FEV1% predicted: 50% ≤ II ≤ 80%; 30% ≤ III ≤ 50%; and IV ≤ 30%
Fig. 3 Circulating IFNL3 during stable COPD, in healthy controls, during
exacerbation and during follow up to exacerbation 4 weeks later
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other SNPs related to IFNL3. In addition, the circulating
IFNL3 was measured from unmatched blood donor
samples. However, we found no association between cir-
culating IFNL3 levels and gender or age, so the differ-
ences seen between the healthy controls and the COPD
patients probably are not due to gender or age differ-
ences. The clinical value of IFNL3 alone or in combin-
ation with other biomarkers has to be assessed in
conformational and randomized clinical trials.
Strengths of the study include the originality, longitu-
dinal design assessing clinically relevant end-points and
the fact that both genotypes and circulating IFNL3 were
determined in a large multicentric cohort.
Conclusions
IFNL3 polymorphisms may play a role in disease activity
and outcomes in COPD and circulating IFNL3 may be
associated with disease severity and stability. Further in-
vestigations are required to determine the underlying
mechanisms.
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